The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Open accessAbstract
The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis. Introduction: RANKL is an essential osteoclastic differentiation and activation factor. Materials and Methods: The bone antiresorptive activity and safety of AMG 162, a fully human monoclonal antibody to RANKL, were evaluated in postmenopausal women in this randomized, double-blind, placebo-controlled, single-dose, dose escalation study. Six cohorts of eight to nine women were randomly assigned to receive a single subcutaneous injection of either AMG 162 or placebo (3:1 ratio). AMG 162 doses were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg. Subjects were followed up to 6 months in all cohorts and 9 months in the three highest dose cohorts. Second morning void urinary N-telopeptide/creatinine (NTX; Osteomark), serum NTX, and serum bone-specific alkaline phosphatase (BALP, Ostase) were assessed as bone turnover markers. Results and Conclusions: Forty-nine women were enrolled. A single subcutaneous dose of AMG 162 resulted in a dose-dependent, rapid (within 12 h), profound (up to 84%), and sustained (up to 6 months) decrease in urinary NTX. At 6 months, there was a mean change from baseline of −81% in the 3.0 mg/kg AMG 162 group compared with −10% in the placebo group; serum NTX changes were −56% and 2%, respectively. BALP levels did not decrease remarkably until after 1 month, indicating that the effect of AMG 162 is primarily antiresorptive. Intact parathyroid hormone (PTH) levels increased up to ∼3-fold after 4 days in the 3.0 mg/kg dose group, but returned toward baseline with follow-up. Albumin-adjusted serum calcium did not decrease >10% on average in any group, and no subject had values below 2 mmol/liter. AMG 162 was well tolerated. No related serious adverse events occurred. No clinically meaningful laboratory changes, other than those described above, were observed. In summary, a single subcutaneous dose of AMG 162 resulted in a dose-dependent rapid and sustained decrease from baseline in bone turnover and could be an effective and convenient treatment for osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 2×
“Genetic experiments have shown that mice with a disrupted RANKL gene have severe osteopetrosis and absence of osteoclasts.((5)) As a soluble member of the TNF receptor family, osteoprotegerin (OPG) blocks bone resorption by binding to RANKL and preventing its interaction with RANK, a cell surface receptor on pre-osteo…”
BackgroundSelf-citationIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citationA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Tetracycline-based histological analysis of bone remodeling
Frost, H. M. (1969) · Calcified Tissue Research · doi:10.1007/bf02058664 · Cited by 1,111 · cited 1×
“Osteoclastic bone resorption on dormant bone surfaces normally initiates the bone turnover cycle, which is followed by osteoblastic bone formation.((39,40)) Therefore, when the activation frequency is decreased, the bone formation rate also decreases as a result.”
BackgroundIntravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Ritchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G., & Schwarz, E. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16069 · Cited by 616
ERIKSEN, E. F. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-4-379 · Cited by 601
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., & Gillespie, M. T. (1999) · Endocrinology · doi:10.1210/endo.140.10.7037 · Cited by 536
Honore, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 498
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Self-citationMutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., MacPherson, H., Wallace, R. G. H., van Hul, W., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 481
Molecular mechanisms of cancer pain
Mantyh, P. W., Clohisy, D. R., Koltzenburg, M., & Hunt, S. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc747 · Cited by 477
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 445
Alendronate Once-Weekly Study Group, Schnitzer, T., Bone, H. G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Recker, R. R., Tonino, R. P., et al. (2000) · Aging Clinical and Experimental Research · doi:10.1007/bf03339822 · Cited by 394
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Self-citationOsteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
Self-citationSkeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6777 · Cited by 335
Brown, J. P., Kendler, D. L., McClung, M. R., Emkey, R. D., Adachi, J. D., Bolognese, M. A., Li, Z., Balske, A., & Lindsay, R. (2002) · Calcified Tissue International · doi:10.1007/s00223-002-2011-8 · Cited by 330
Chesnut, C. H., Bell, N. H., Clark, G. S., Drinkwater, B. L., English, S. C., Johnston, C. C., Notelovitz, M., Rosen, C., Cain, D. F., Flessland, K. A., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00387-7 · Cited by 282
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Osteoprotegerin and RANK ligand expression in prostate cancer.
Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01122-5 · Cited by 234
Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., Atkins, G. J., & Findlay, D. M. (2001) · Rheumatology · doi:10.1093/rheumatology/40.6.623 · Cited by 216
Johnston, C. C., Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath, H., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3444 · Cited by 211
Osteoprotegerin diminishes advanced bone cancer pain.
Luger, N. M., Honoré, P., Sabino, M., Schwei, M. J., Rogers, S. D., Mach, D. B., Clohisy, D. R., & Mantyh, P. W. (2001) · PubMed · Cited by 211
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187
Self-citationCrotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., & Findlay, D. M. (2001) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.83b6.0830902 · Cited by 186
RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa, S., & Kitazawa, R. (2002) · The Journal of Pathology · doi:10.1002/path.1199 · Cited by 141
Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140
Self-citationMancino, A. T., Klimberg, V. S., Yamamoto, M., Manolagas, S. C., & Abe, E. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6204 · Cited by 138
Comparison of analytical performance and biological variability of three bone resorption assays
Ju, H.-S. J., Leung, S., Brown, B. A., Stringer, M. A., Leigh, S. D., Scherrer, C., Shepard, K., Jenkins, D. K., Knudsen, J., & Cannon, R. M. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.9.1570 · Cited by 127
RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.
Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125
Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105
Eastell, R., Mallinak, N. J. S., Weiss, S., Ettinger, M. P., Pettinger, M. B., Cain, D. F., Flessland, K. A., & Chesnut, C. H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.3.594 · Cited by 94
Sparks, A. B., Peterson, S. N., Bell, C., Loftus, B., Hocking, L. J., Cahill, D. P., Frassica, F. J., Streeten, E. A., Levine, M. A., Fraser, C. M., et al. (2001) · Calcified Tissue International · doi:10.1007/s002230001211 · Cited by 83
Clohisy, D. R., Ramnaraine, M. L. R., Scully, S. A., Qi, M., Van, G. Y., Tan, H. L. E., & Lacey, D. L. (2000) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100180617 · Cited by 45
Gravellese (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200002)43:2 · Cited by 2
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Self-citation
Metadata
- Authors
- Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 19
- Issue
- 7
- Pages
- 1059-1066
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2048346627
- Cited by
- 771
- References
- 50
- FWCI
- 47.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.